Aleksandar Videnovic, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
REM Sleep Behavior Disorder | 27 | 2024 | 105 | 7.050 |
Why?
|
Parkinson Disease | 46 | 2023 | 2785 | 6.260 |
Why?
|
Disorders of Excessive Somnolence | 9 | 2022 | 271 | 2.970 |
Why?
|
Circadian Rhythm | 14 | 2023 | 2620 | 2.770 |
Why?
|
Phototherapy | 7 | 2020 | 377 | 2.370 |
Why?
|
Neurodegenerative Diseases | 8 | 2023 | 1060 | 2.340 |
Why?
|
Chronobiology Disorders | 4 | 2021 | 74 | 1.890 |
Why?
|
Sleep, REM | 10 | 2023 | 592 | 1.430 |
Why?
|
Sleep Disorders, Circadian Rhythm | 3 | 2019 | 222 | 1.340 |
Why?
|
Melatonin | 4 | 2021 | 721 | 1.180 |
Why?
|
Lewy Body Disease | 4 | 2023 | 229 | 1.170 |
Why?
|
Huntington Disease | 4 | 2023 | 1124 | 1.080 |
Why?
|
Sleep | 10 | 2023 | 4619 | 0.920 |
Why?
|
Sodium Oxybate | 1 | 2023 | 32 | 0.900 |
Why?
|
Narcolepsy | 2 | 2023 | 195 | 0.890 |
Why?
|
Multiple System Atrophy | 3 | 2023 | 120 | 0.880 |
Why?
|
Pantothenate Kinase-Associated Neurodegeneration | 4 | 2021 | 14 | 0.750 |
Why?
|
Cell Adhesion Molecules, Neuronal | 1 | 2022 | 266 | 0.730 |
Why?
|
Carbamates | 1 | 2021 | 196 | 0.700 |
Why?
|
Phenylalanine | 1 | 2021 | 365 | 0.700 |
Why?
|
Chronotherapy | 1 | 2019 | 10 | 0.690 |
Why?
|
Circadian Clocks | 2 | 2021 | 171 | 0.590 |
Why?
|
Gait Disorders, Neurologic | 4 | 2022 | 233 | 0.570 |
Why?
|
Restless Legs Syndrome | 4 | 2021 | 228 | 0.560 |
Why?
|
Patient Care Management | 1 | 2019 | 306 | 0.540 |
Why?
|
Multiple Sclerosis | 2 | 2020 | 3079 | 0.470 |
Why?
|
Fatigue | 2 | 2020 | 1530 | 0.470 |
Why?
|
Dopamine | 3 | 2021 | 1592 | 0.460 |
Why?
|
Autoantibodies | 1 | 2022 | 2037 | 0.450 |
Why?
|
Polysomnography | 10 | 2023 | 1776 | 0.440 |
Why?
|
alpha-Synuclein | 2 | 2023 | 723 | 0.430 |
Why?
|
Exercise Therapy | 1 | 2019 | 904 | 0.410 |
Why?
|
Gait | 3 | 2022 | 795 | 0.380 |
Why?
|
Autoimmune Diseases | 1 | 2022 | 2134 | 0.350 |
Why?
|
Quality of Life | 7 | 2022 | 12788 | 0.350 |
Why?
|
Humans | 82 | 2024 | 743811 | 0.340 |
Why?
|
Sleep Stages | 2 | 2012 | 685 | 0.330 |
Why?
|
Brain | 7 | 2021 | 26345 | 0.320 |
Why?
|
Movement Disorders | 1 | 2011 | 448 | 0.300 |
Why?
|
Immunotherapy | 1 | 2022 | 4437 | 0.270 |
Why?
|
Depressive Disorder | 1 | 2019 | 3744 | 0.270 |
Why?
|
Clinical Trials as Topic | 2 | 2020 | 7908 | 0.250 |
Why?
|
Actigraphy | 2 | 2018 | 488 | 0.230 |
Why?
|
Parasomnias | 1 | 2024 | 26 | 0.230 |
Why?
|
Severity of Illness Index | 9 | 2022 | 15526 | 0.230 |
Why?
|
Pantothenic Acid | 2 | 2020 | 18 | 0.220 |
Why?
|
Aged | 28 | 2023 | 163178 | 0.220 |
Why?
|
Dopamine Plasma Membrane Transport Proteins | 2 | 2021 | 422 | 0.200 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2005 | 640 | 0.200 |
Why?
|
Dopamine Agonists | 2 | 2021 | 355 | 0.200 |
Why?
|
Flecainide | 1 | 2021 | 42 | 0.200 |
Why?
|
Neurotoxicity Syndromes | 1 | 2005 | 290 | 0.200 |
Why?
|
Attitude to Health | 1 | 2011 | 2052 | 0.200 |
Why?
|
Motor Neuron Disease | 1 | 2022 | 99 | 0.200 |
Why?
|
Deoxycytidine | 1 | 2005 | 826 | 0.200 |
Why?
|
Tissue Donors | 1 | 2011 | 2241 | 0.200 |
Why?
|
Autonomic Nervous System Diseases | 1 | 2023 | 258 | 0.190 |
Why?
|
Inosine | 1 | 2021 | 133 | 0.190 |
Why?
|
Hypotension, Orthostatic | 1 | 2023 | 255 | 0.190 |
Why?
|
Benzofurans | 1 | 2021 | 140 | 0.190 |
Why?
|
Muscle Rigidity | 1 | 2020 | 35 | 0.190 |
Why?
|
Muscle Tonus | 1 | 2020 | 81 | 0.180 |
Why?
|
Nervous System Diseases | 3 | 2019 | 1619 | 0.180 |
Why?
|
Double-Blind Method | 7 | 2023 | 12020 | 0.180 |
Why?
|
Deep Brain Stimulation | 1 | 2008 | 761 | 0.180 |
Why?
|
Cyclopropanes | 1 | 2021 | 415 | 0.170 |
Why?
|
Glucosylceramidase | 1 | 2020 | 125 | 0.170 |
Why?
|
Emotions | 1 | 2011 | 2656 | 0.170 |
Why?
|
Middle Aged | 27 | 2023 | 213241 | 0.170 |
Why?
|
Mental Status Schedule | 2 | 2010 | 321 | 0.160 |
Why?
|
Self Report | 2 | 2022 | 3550 | 0.160 |
Why?
|
Activities of Daily Living | 4 | 2023 | 2419 | 0.160 |
Why?
|
Male | 30 | 2023 | 349776 | 0.150 |
Why?
|
Alzheimer Disease | 3 | 2023 | 8035 | 0.150 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2022 | 652 | 0.150 |
Why?
|
Cognition Disorders | 2 | 2020 | 4041 | 0.150 |
Why?
|
Dementia | 2 | 2023 | 2518 | 0.150 |
Why?
|
Neuropsychological Tests | 1 | 2010 | 6976 | 0.140 |
Why?
|
Vitamin B Complex | 1 | 2019 | 288 | 0.140 |
Why?
|
Female | 31 | 2024 | 380020 | 0.140 |
Why?
|
Animals | 11 | 2023 | 168660 | 0.140 |
Why?
|
Disability Evaluation | 2 | 2017 | 1828 | 0.140 |
Why?
|
Uric Acid | 1 | 2021 | 765 | 0.130 |
Why?
|
Sleep Apnea Syndromes | 3 | 2017 | 944 | 0.130 |
Why?
|
Behavior Therapy | 1 | 2021 | 862 | 0.130 |
Why?
|
Research Design | 3 | 2020 | 5983 | 0.120 |
Why?
|
Adult | 16 | 2021 | 213889 | 0.120 |
Why?
|
Disease Progression | 5 | 2023 | 13273 | 0.110 |
Why?
|
Brain Stem | 3 | 2021 | 844 | 0.110 |
Why?
|
Amantadine | 1 | 2012 | 55 | 0.110 |
Why?
|
Period Circadian Proteins | 1 | 2013 | 102 | 0.110 |
Why?
|
Suprachiasmatic Nucleus | 1 | 2013 | 147 | 0.100 |
Why?
|
Muscle Hypotonia | 1 | 2013 | 165 | 0.100 |
Why?
|
Clinical Protocols | 1 | 2018 | 1459 | 0.100 |
Why?
|
gamma-Aminobutyric Acid | 1 | 2017 | 1118 | 0.100 |
Why?
|
Isradipine | 1 | 2010 | 14 | 0.100 |
Why?
|
Registries | 2 | 2019 | 8090 | 0.100 |
Why?
|
Cross-Sectional Studies | 6 | 2023 | 25032 | 0.090 |
Why?
|
Disease Models, Animal | 2 | 2023 | 18027 | 0.090 |
Why?
|
Sleep Apnea, Obstructive | 1 | 2023 | 1813 | 0.090 |
Why?
|
Cardiovascular Diseases | 1 | 2015 | 15142 | 0.090 |
Why?
|
Neural Pathways | 1 | 2020 | 2971 | 0.090 |
Why?
|
Mass Screening | 2 | 2018 | 5251 | 0.080 |
Why?
|
Cohort Studies | 6 | 2019 | 40545 | 0.080 |
Why?
|
Electromyography | 1 | 2013 | 1378 | 0.080 |
Why?
|
Young Adult | 5 | 2019 | 56392 | 0.080 |
Why?
|
Sleep Initiation and Maintenance Disorders | 1 | 2017 | 1004 | 0.080 |
Why?
|
PubMed | 1 | 2008 | 121 | 0.080 |
Why?
|
Calcium Channel Blockers | 1 | 2010 | 692 | 0.070 |
Why?
|
Treatment Outcome | 5 | 2023 | 63042 | 0.070 |
Why?
|
Globus Pallidus | 1 | 2008 | 253 | 0.070 |
Why?
|
Neuroprotective Agents | 1 | 2013 | 941 | 0.070 |
Why?
|
Retina | 1 | 2017 | 2612 | 0.070 |
Why?
|
Patient Compliance | 1 | 2017 | 2683 | 0.070 |
Why?
|
Diagnosis, Differential | 1 | 2022 | 12954 | 0.070 |
Why?
|
Disease Management | 1 | 2017 | 2459 | 0.070 |
Why?
|
Movement | 2 | 2024 | 1471 | 0.070 |
Why?
|
Heart Rate | 1 | 2017 | 4091 | 0.070 |
Why?
|
HELLP Syndrome | 1 | 2005 | 41 | 0.070 |
Why?
|
Neurologic Examination | 2 | 2020 | 929 | 0.060 |
Why?
|
Subthalamic Nucleus | 1 | 2008 | 188 | 0.060 |
Why?
|
Patient Selection | 1 | 2017 | 4210 | 0.060 |
Why?
|
West Nile Fever | 1 | 2005 | 78 | 0.060 |
Why?
|
Reproducibility of Results | 1 | 2023 | 19894 | 0.060 |
Why?
|
Antiparkinson Agents | 2 | 2017 | 186 | 0.060 |
Why?
|
Counseling | 2 | 2023 | 1523 | 0.060 |
Why?
|
Serotonin 5-HT2 Receptor Antagonists | 1 | 2023 | 21 | 0.060 |
Why?
|
Electrocardiography | 1 | 2017 | 6441 | 0.060 |
Why?
|
Longitudinal Studies | 4 | 2023 | 13980 | 0.050 |
Why?
|
Aging | 2 | 2015 | 8655 | 0.050 |
Why?
|
Cholinesterase Inhibitors | 1 | 2023 | 238 | 0.050 |
Why?
|
Withholding Treatment | 1 | 2005 | 599 | 0.050 |
Why?
|
Fluorouracil | 1 | 2005 | 1619 | 0.050 |
Why?
|
Aged, 80 and over | 6 | 2020 | 57744 | 0.050 |
Why?
|
Health Surveys | 1 | 2011 | 4036 | 0.050 |
Why?
|
North America | 1 | 2024 | 1249 | 0.050 |
Why?
|
Prognosis | 4 | 2023 | 29052 | 0.040 |
Why?
|
Intracranial Hemorrhages | 1 | 2005 | 855 | 0.040 |
Why?
|
Depression | 1 | 2019 | 7760 | 0.040 |
Why?
|
Genetic Counseling | 1 | 2023 | 600 | 0.040 |
Why?
|
Retrospective Studies | 5 | 2018 | 77410 | 0.040 |
Why?
|
Phosphotransferases (Alcohol Group Acceptor) | 1 | 2021 | 437 | 0.040 |
Why?
|
Consensus | 2 | 2019 | 2954 | 0.040 |
Why?
|
Kidney Calculi | 1 | 2021 | 465 | 0.040 |
Why?
|
Disclosure | 1 | 2023 | 737 | 0.040 |
Why?
|
Dopamine Agents | 1 | 2017 | 189 | 0.030 |
Why?
|
Drug Combinations | 1 | 2021 | 1958 | 0.030 |
Why?
|
Reaction Time | 1 | 2022 | 2091 | 0.030 |
Why?
|
Parkinsonian Disorders | 1 | 2019 | 278 | 0.030 |
Why?
|
Mutation | 1 | 2020 | 29777 | 0.030 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 1 | 2020 | 1108 | 0.030 |
Why?
|
Treatment Failure | 1 | 2021 | 2617 | 0.030 |
Why?
|
Upper Extremity | 1 | 2020 | 647 | 0.030 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2019 | 841 | 0.030 |
Why?
|
Follow-Up Studies | 4 | 2020 | 39001 | 0.030 |
Why?
|
Neoplasm Metastasis | 1 | 2005 | 4848 | 0.030 |
Why?
|
Adolescent | 4 | 2019 | 85729 | 0.030 |
Why?
|
Multicenter Studies as Topic | 1 | 2019 | 1676 | 0.030 |
Why?
|
Carcinoma | 1 | 2005 | 2375 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2021 | 9944 | 0.030 |
Why?
|
Clonazepam | 1 | 2013 | 136 | 0.030 |
Why?
|
Creatine | 1 | 2015 | 421 | 0.030 |
Why?
|
Phenotype | 2 | 2021 | 16361 | 0.030 |
Why?
|
GABA Modulators | 1 | 2013 | 107 | 0.030 |
Why?
|
Iron | 1 | 2021 | 1774 | 0.030 |
Why?
|
Quantitative Trait Loci | 1 | 2020 | 2018 | 0.030 |
Why?
|
Autonomic Nervous System | 1 | 2017 | 671 | 0.030 |
Why?
|
Health Status | 1 | 2005 | 4031 | 0.030 |
Why?
|
Comorbidity | 2 | 2017 | 10380 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 3 | 2021 | 35409 | 0.020 |
Why?
|
Prospective Studies | 3 | 2023 | 53250 | 0.020 |
Why?
|
Prevalence | 1 | 2008 | 15211 | 0.020 |
Why?
|
Amyloid beta-Peptides | 1 | 2023 | 3587 | 0.020 |
Why?
|
Genetic Association Studies | 1 | 2020 | 2703 | 0.020 |
Why?
|
Internationality | 1 | 2016 | 1002 | 0.020 |
Why?
|
Social Class | 1 | 2019 | 1997 | 0.020 |
Why?
|
Forecasting | 1 | 2019 | 2950 | 0.020 |
Why?
|
Artificial Intelligence | 1 | 2022 | 2210 | 0.020 |
Why?
|
Case-Control Studies | 2 | 2017 | 21733 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2019 | 6539 | 0.020 |
Why?
|
Pancreatic Neoplasms | 1 | 2005 | 5264 | 0.020 |
Why?
|
Child | 3 | 2019 | 77637 | 0.020 |
Why?
|
Genetic Testing | 1 | 2019 | 3439 | 0.020 |
Why?
|
Cognition | 1 | 2022 | 6759 | 0.020 |
Why?
|
West Nile virus | 1 | 2005 | 79 | 0.020 |
Why?
|
Muscle, Skeletal | 1 | 2020 | 4925 | 0.020 |
Why?
|
Sex Characteristics | 1 | 2015 | 2583 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2017 | 10940 | 0.020 |
Why?
|
Hypertension | 2 | 2005 | 8480 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2019 | 12354 | 0.020 |
Why?
|
Electronic Health Records | 1 | 2019 | 4467 | 0.010 |
Why?
|
Rats, Inbred WKY | 1 | 2000 | 158 | 0.010 |
Why?
|
Rats, Inbred SHR | 1 | 2000 | 195 | 0.010 |
Why?
|
Demography | 1 | 2005 | 1653 | 0.010 |
Why?
|
Age Factors | 1 | 2017 | 18355 | 0.010 |
Why?
|
Risk Factors | 2 | 2019 | 72252 | 0.010 |
Why?
|
Breast Neoplasms | 1 | 2005 | 20827 | 0.010 |
Why?
|
Pilot Projects | 1 | 2010 | 8316 | 0.010 |
Why?
|
Headache | 1 | 2005 | 1224 | 0.010 |
Why?
|
Respiratory Insufficiency | 1 | 2005 | 1199 | 0.010 |
Why?
|
Mice | 1 | 2022 | 81154 | 0.010 |
Why?
|
United States | 1 | 2019 | 69859 | 0.010 |
Why?
|
Rats | 1 | 2000 | 24250 | 0.000 |
Why?
|
Pregnancy | 1 | 2005 | 29140 | 0.000 |
Why?
|